Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe

Summary

The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents.

In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases.

In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs.

Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

Conditions

• COVID-19
• Systemic Lupus Erythematosus
• Sjogren's Syndrome
• Axial Spondyloarthritis
• Rheumatoid Arthritis
• Giant Cell Arteritis

Sponsors & Collaborators

• Università degli Studi di Ferrara

  collaborator OTHER

• Rheumazentrum Ruhrgebiet

  collaborator OTHER

• University College, London

  collaborator OTHER

• University of Coimbra

  collaborator OTHER

• Universidad Complutense de Madrid

  collaborator OTHER

• Pitié-Salpêtrière Hospital

  lead OTHER

Principal Investigators

• David Saadoun, MD, PhD · Pitié-Salpêtrière Hospital

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-06-10

Primary Completion

2020-12-08

Completion

2021-01-31

Countries

• France

Study Locations